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Background: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of 
patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. 
Such delays can lead to disease progression.  
Objective: We aimed to develop guidance on criteria for prioritization for surgery and reconfiguring 
management pathways for non-metastatic stage of prostate cancer who opt for surgical treatment. A 
second aim was to identify the infection prevention and control (IPC) measures to achieve low 
likelihood of COVID-19 hazard if radical prostatectomy was to be carried out during the outbreak and 
whilst the disease is endemic. 
Design, Setting and Participants: An accelerated consensus process and systematic review.  We 
conducted a systematic review of the evidence on COVID-19 and reviewed international guidance on 
prostate cancer. These were presented to an international prostate cancer expert panel (n=34) through 
an online meeting. The consensus process underwent three rounds of survey in total. Additions to the 
second- and third-round surveys were formulated based on the answers and comments from the 
previous rounds.  
Outcome Measures: Consensus opinion was defined as ≥80% agreement, which were used to 
reconfigure the prostate cancer pathways. 
Results: Evidence on the delayed management of patients with prostate cancer is scarce. There was 
100% agreement that prostate cancer pathways should be reconfigured and develop measures to 
prevent nosocomial COVID-19 for patients treated surgically. Consensus was reached on 
prioritization criteria of patients for surgery and management pathways for those who have delayed 
treatment. IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as 
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Conclusion: Re-configuring management pathways for prostate cancer patients is recommended if 
significant delay (>3-6 months) in surgical management is unavoidable. The mapped pathways 
provide guidance for such patients. The IPC processes proposed provide a framework for providing 
radical prostatectomy within an environment with low COVID-19 risk during the outbreak or when 
the disease remains endemic. The broader concepts could be adapted to other indications beyond 
prostate cancer surgery. 
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1 Introduction 
The coronavirus disease-19 (COVID-19) pandemic has affected healthcare at multiple levels with 
inevitable delays in provision of care for patients with other conditions, such as cancer . This includes 
men with non-metastatic prostate cancer who are awaiting surgical treatment (1, 2). Prostate cancer  is 
a heterogenous disease, with a global annual incidence of 1.3 million and 419,000 deaths per annum 
(3). Non-metastatic prostate cancer is categorized into three main groups (low, intermediate and high) 
based on risk of disease progression (4, 5). Radical treatment, including surgery or radiotherapy, 
mostly benefits men with intermediate or high-risk disease with a life-expectancy of  over 10 years 
(5). Prolonged delay in treatment will probably result in disease progression with consequent loss of 
ability to preserve peri-prostatic structures impacting on functional outcomes. Furthermore, the 
expected duration of delays to curative treatment remains unclear but any delay will result in a 
backlog of the number of men awaiting radical treatment. Delays to the diagnostic pathway from 
prostate specific antigen (PSA) testing to biopsy will also add to the backlog and result in later 
presentation of more advanced disease, which poses a risk to patient wellbeing. Mitigation of these 
risks during the COVID-19 pandemic necessitate reconfiguration of management pathways and 
development of  strategies to prioritize patients. An additional challenge is the need to protect both 
patients and healthcare workers from contracting COVID-19 until the disease is either eradicated or 
vaccines are developed whilst ensuring the safe delivery of radical treatment for those in need. 
The first aim of this study was to develop guidance on reconfiguring the management pathways for 
prostate cancer patients with non-metastatic disease whose radical surgical treatment is delayed due to 
the COVID-19 outbreak. A second aim was to identify the basic requirements of achieving low 
likelihood of COVID-19 hazard within a health care unit intending to offer prostate cancer surgery 
whilst the corona virus remains in population (a so-called COVID-19 “cold” site). We used an 
accelerated consensus by adapting the Delphi methodology to provide guidance in the absence of 
substantial evidence during the COVID-19 outbreak. In addition, we hope that the infection 
prevention and control principles (IPC) will be of relevance for other specialties planning to deliver 
surgery as long as COVID-19 remains in community without definitive treatments or vaccines. 
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2 Material and methods 
The study consisted of three objectives where each phase informed the subsequent phase. First, a 
systematic review of the literature and current published guidelines was completed in accordance with 
the PRISMA statement (6). Second, the systematic review informed a series of questions from which 
answers by consensus was sought. Third, the obtained consensus, in turn, helped map a pathway for 
the reconfiguration of prostate cancer management for patients who opt for surgery if a backlog 
develops during the COVID-19 outbreak and establish the components for how to deliver surgery 
whilst COVID-19 can spread in community.  
2.1 Evidence synthesis: COVID-19 & Prostate Cancer 
The first teleconference was conducted on Saturday April 4
th
 2020 and the second on Tuesday April 
7
th
 2020. At the inception of this project there was limited evidence published for COVID-19 and its 
impact on surgery. The available evidence was used to develop questionnaires for the Delphi 
consensus process. This process was carried out by authors with expertise in infectious diseases (ZT, 
PH, JR, TEBJ, FW, BK). A systematic review of the literature was carried out using MEDLINE 
(accessed from PubMed to identify published articles from January 01, 2020 to March 30, 2020 
(further details in Supplement I). Guidelines and recommendations regarding COVID-19 published by 
World Health Organization (WHO), Center for Disease Control (CDC), European Center for Disease 
Control (ECDC) and National Institute for Clinical Excellence (NICE) were reviewed. Publications 
identified from reference lists of these documents were also reviewed.  
The aim of this evidence synthesis work was to identify questions relevant to: 
a) Frequency of asymptomatic COVID-19 patients 
b) Incubation period of COVID-19 
c) Sensitivity and specificity of available diagnostic tests for COVID-19 in asymptomatic 
patients 
d) Stages of contagiousness  
e) Duration of contagiousness 
f) Risk factors for severe outcomes in patients who develop COVID-19 
g) In hospital IPC measures that can be implemented to establish an environment protective for 
both the patient and health care workforce before, during and after radical prostatectomy 
h) Prostate cancer management guidelines, to review existing pathways and suggest 
modification in order to minimize risk during the pandemic (supplement II) 
The prostate cancer guidelines and recommendations published by the European Association of 
Urology (EAU) and National Comprehensive Caner Network (NCCN) were reviewed (ZT, JC, GS). 
Information summarized by these documents was used to establish the baseline of current expected 
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2.2 Expert panel teleconference meeting  
An advisory panel was formed that was comprised of key opinion leaders with a specialist expertise in 
infectious diseases, prostate cancer management and/or robotic surgery programs (supplement III). 
J.K., P.H., J.C. and Z.T. chaired panels. In total thirty-eight experts from four continents including 
seven countries from Europe (Belgium, Germany, Hungary, Italy, Netherlands, Norway, UK) were 
brought together to discuss and develop an international standard for the development of a cold site 
for managing prostate cancer during the pandemic. At the time of the consensus, Europe was at the 
centre of the pandemic and experts were selected from countries with different healthcare contexts to 
allow generalizability of findings. Experts with recent experience in managing PC patients during the 
COVID-19 crisis were included (Italy/Spain/New York/ California). Thirty-six panel members were 
qualified as surgeons (including four members of the EAU section of Infections in Urology, for which 
three have expertise in nosocomial infections) and two were experts on infection prevention and 
control as well as virology (supplement III for composition of panel and roles). The teleconference 
meetings comprised presentations (supplement IV) on the subject matter, clarifications of current 
evidence and reviews of the literature findings. Overviews of the various strategies development of 
“COVID-19 cold” sites were discussed. 
2.3 Internet survey and consensus process  
Following the teleconference, the consensus process was conducted amongst the experts. An internet 
survey (Google forms) was generated and sent to the 34 members of the panel (Supplement V). An 
accelerated e-consensus-reaching exercise, over three consecutive days, by using the Delphi 
methodology, was then applied (7). The Delphi method structures group communications so that the 
process is effective in allowing a group of individuals to deal with a complex problem. We consented 
participants prior to the process and its time points. This was particularly important in accelerating the 
process.  
Questions in which there was ≥80% consensus were removed from the next round of the survey. 
Repeated iterations of anonymous voting continued over three rounds, where an individual’s vote in 
the next round was informed by knowledge of the entire group’s results in the previous round. To be 
included in the final recommendations each survey item had to have reached group consensus (≥80% 
agreement) by the end of the three survey rounds. In the Delphi process the finding of ‘consensus’ is 
more relevant than the level of consensus. Levels of consensus are reported in Supplement V.  
The process applied adhered to the principles of Delphi methodology of, (i) selection of panel 
members -experts, (ii) development and application of questions in rounds (iii) evolution of responses 
and (iv) divergence towards a consensus (7). Although, the implementation of a Delphi process can be 
variable, the strict time frames we applied is novel. Therefore, we have coined the process as a 
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2.4 Pathway development  
The purpose of the pathway development and mapping is to systematically assemble evidence to 
provide guidance for clinicians. The existing pathways were reviewed and reconfigured using 
available evidence, published similar pathways and input from the consensus process (4, 5, 8). 
Subsequent to the consensus process, plausible scenarios to plan for delays in radical surgical 
treatment from the point of risk stratification of prostate cancer onwards were illustrated in a one-page 
comprehensive flow-chart. This was an iterative process whereby the consensus panel was consulted 
to review the prepared pathway until agreement was reached.  
3 Findings 
3.1 Evidence and guidance for COVID-19  
The evidence acquisition process included 2,430 records reviewed and 30 full texts were used (Figure 
1). Further studies and recommendations were obtained from WHO, CDC, ECDC and NICE. 
Findings are provided in Supplement-I. 
3.2 Consensus process 
Consensus was reached on multiple items (84.3%, n=75/89). Results of the three rounds are 
summarized in Figure 2 and details are provided in supplement V. The main statements of the 
consensus process are summarized in Table 1Error! Reference source not found.. A detailed 
summary of the statements is provided in supplement VI. 
3.2.1 Delivery of surgery 
The panel reached consensus on multiple items that collectively contribute to re-arranging a hospital 
site to deliver radical prostate surgery within a COVID-19 protected environment. These are 
summarized in Table 1 and the panel agreed to define such sites that adhere to the principles as 
“COVID-19 cold”. The panel reached consensus that resource allocation to “COVID-19 cold” sites 
should be guided by the resource requirement of COVID-19 patients in individual regions and 
countries. 
Principles of patient flow prior, during and after surgery are dependent on the sensitivity and 
specificity of COVID-19 diagnostic tests as well as the time taken to obtain results. At the time of 
manuscript preparation there remained a paucity of rapid tests with a high sensitivity and specificity. 
Therefore, the panel agreed on a set of basic principles and assumptions to be used to keep the risk of 
COVID-19 as low as possible within the “COVID -19 cold” sites. The principles that were agreed on 
include accounting for the incubation period of COVID-19, the need to operate on patients with 
minimal risk of contagiousness, and isolation of patients after surgery until catheter is removed (on 
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to ensure that surgery is performed on patients with the least likelihood of contagiousness. Based on 
the discussions and the reviewed literature the scenarios discussed are illustrated in Figure 2. 
3.2.2 Rationing prostate cancer surgery 
Panel reached consensus on rationing prostate cancer patients using the EAU risk classification tool, 
age and risk factors for COVID-19 worse outcomes. Statements agreed are provided in Table 1. A 
conceptual summary of the agreed principles is summarized in Figure 3. 
3.2.3 Re-configuration of management pathways  
Consensus was achieved to re-arrange pathways for patients whose definitive treatment will be 
postponed using the EAU risk stratification. A conceptual pathway that was mapped based on the 
panel consensus, and is provided in Figure 4 and details of statements, in Table 1. Discussion  
 
4 Discussion 
In this study an international expert panel developed consensus statements to reconfigure surgical 
pathways if there was a delay due to the impact of the COVID-19 outbreak. This challenging task was 
achieved through an accelerated consensus process. The statements were developed with the intention 
to be utilized as part of a comprehensive response to maintain essential healthcare services while 
simultaneously ensuring care for acutely ill COVID-19 patients. The ability of a country to maintain 
essential health care services will be influenced by its underlying resources, incidence of COVID-19 
and other cases. Therefore, the consensus was developed to address re-organization of the pathways 
of prostate cancer patients who opt for surgery until health-care systems resume routine services. In 
addition, throughout the outbreak there will be variability in the strategic allocation of resources 
dependent on the incidence of COVID-19. The panel has agreed to ration cases for surgery and the 
underlying concepts to achieve this in a protected environment that minimise risk to the patient and 
healthcare staff to additional adverse outcomes of COVID-19. These will be helpful for countries that 
can allocate resources for cancer surgery during the different stages of the pandemic. Beyond this the 
rationing strategy for prostate surgery cancer will remain relevant once the pandemic is over in 
prioritizing patients within the backlog. 
We reached consensus on multiple items related to delivery of surgery and postoperative care, if 
possible, during the outbreak. Two key concepts that were agreed largely shape the remaining 
statements of the consensus for delivery of surgery. The first concept is to simultaneously ensure 
safety of the patient and healthcare staff regarding COVID-19 (i.e. prevention and control of 
nosocomial COVID-19). The second concept is to assume that at any given time point a patient or 
healthcare professional can be contagious. Lack of rapid and accurate diagnostics shaped these 
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distinguish if individuals are contagious or not. Viral RNA detection methods can identify individuals 
shedding the virus but this does not necessarily indicate contagiousness(9). Lack of reliable serology 
tests and unknown duration of contagiousness after COVID-19 are additional complexities that the 
panel considered. Nosocomial infections of the virus within a “COVID-19 cold” site delivering 
elective prostate cancer surgery could result in serious consequences and defeat the purpose of such a 
site. Initial series indicate that in COVID-19 treatment sites nosocomial infection rate could be up to 
41%(10). Concepts adopted by the panel can be considered as a safe option that maintains the 
“COVID-19 cold” site functional throughout the outbreak until the corona virus is either eradicated 
from community or vaccine is developed. However, these concepts generate significant operational 
challenges including reconfiguration of the work and patient flow and utilization of large amounts of 
personal protective equipment (PPE). 
Concerns of inadequate global PPE stockpiles mean that effective and appropriate use of PPE is 
imperative to maintain safe healthcare provision as long as COVID-19 remains in community (11). 
Adjustment of PPE composition based on likelihood of contagiousness was successful during the 
2015 Middle Eastern Respiratory Syndrome outbreak and similar approaches can be adopted for 
“COVID-19-cold” sites to ensure efficient use of PPE(12).  Due to absence of definitive diagnostics a 
combination of measures can be utilized to decrease the likelihood of COVID-19 contagiousness of 
an individual and guide PPE use. A key strategy can be isolation of the patient prior to surgery in 
combination with diagnostics (summarized in Figure 2 and supplement-VII). We failed to reach 
consensus on isolating patients for 48 hours in a designated room (external to but near the hospital) 
and screening the surgical candidate at entry and end of isolation. At the final consensus meeting it 
became apparent that panel members who rejected this statement were concerned that infrastructure to 
deliver this was not available at their own site. Current knowledge indicates that the incubation period 
on average is 5 days but this can extend up to 14 days(13). Therefore, the safest duration of pre-
operative isolation would be 14 days. This could be combined with an RNA-viral test at the beginning 
and end of isolation if resources allowed. Isolation of patients can be carried out in single isolation 
rooms or cohort rooms based on IPC guidance(14). Our panel also suggested that countries that can’t 
provide the required resources for patients to isolate in hospital prior to surgery should instead, advise 
patients to self-isolate at home. Countries will need to adapt these recommendations to what is 
achievable within their means. The success of self-isolation at home prior to surgery relies on the 
compliance of patients. To improve compliance to quarantine of suspected cases Taiwan utilized 
mobile tracking technology to monitor patient movements(15). Interventions to improve compliance 
to self-isolation at home prior to surgery will be a challenge that needs to be addressed uniquely for 
each country and culture. Overall, the success of a “COVID-19 cold” site will be dependent on the 
applied process, hospital resources, efficient use of PPE and compliance with the recommendations 
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recommendations to decrease PPE consumption during surgery such as placing the robotic surgical 
console in a separate room and utilizing telemedicine as suggest by WHO(11, 16). This would be 
subject to local regulations.   
Reconfiguration of patient and healthcare staff flow is a vital IPC measure to achieve and protect a 
“COVID-19 cold” site. A hospital in Sichuan, China, applied rigorous IPC measures including 
reconfiguration of flow within an emergency radiology department, succeeding in protecting all 
healthcare staff from COVID-19 despite carrying out 3,340 CT scans on COVID-19 suspected cases 
within 47 days (17). Our panel agreed to take further measures to control staff flow, such as changing 
working shifts to a week or beyond and reside at the hospital site. It is expected that this can help in 
effective resource allocation by negating the need for frequent screening of healthcare staff and 
reduce risk of transmission of COVID-19.  
Decrease in available resources to maintain essential health care services, limited PPE supply and risk 
of COVID-19 adverse outcomes in the general population have created the urgent need to ration 
prostate cancer surgery(11, 18).  We agreed that the decision to offer prostate cancer surgery during 
the pandemic should be made by weighing up the risk of prostate cancer disease progression and the 
risk of COVID-19 adverse effects (Figure 4). Of note, it is currently unclear whether surgery during 
the pandemic increases the risk of mortality from COVID-19. Although a recent paper based upon a 
small heterogenous cohort of COVID-19 confirmed cases undergoing elective surgery at an early time 
point during the current pandemic has indicated that this could be the case(19), however selection bias 
within this cohort limits our ability to refute or support this hypothesis. Nevertheless, patients who 
developed severe COVID-19 features within this surgical cohort tended to be older patients with one 
or more co-morbidities. Our proposed approach to select patients for prostate cancer surgery during 
the pandemic prioritizes younger patients with higher risk disease with only one or zero co-
morbidities. 
Prostate cancer risk stratification was considered to play a crucial role in selecting patients most likely 
to benefit from surgery during the pandemic. The panel agreed that patients with low risk disease 
should be placed on active surveillance protocols, irrespective of their preference for immediate 
surgery.  This is supported by findings from e.g. the PIVOT study reporting only minor survival 
benefit amongst patients with low-risk disease treated with surgery(20). We agreed that NCCN 
criteria can be used to further subgroup the intermediate-risk patients and active surveillance can be 
offered to the favorable group per results from the PROTECT trial(21) and observational data(4, 22). 
Furthermore, inaccurate initial disease staging is known to result in subsequent upstaging in 
approximately 30% patients with intermediate-risk disease(23). Beyond that there is concern that non-
targeted biopsies and absence of MRI scans for staging can miss extra prostatic extension(24). Thus, 
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repeat staging with MRI at 6 months if available. The proposed pathway advises that patients 
upstaged at this point should be offered immediate definitive treatment or ADT, after weighing up the 
risk of COVID19 adverse effects. 
Patients with non-metastatic high-risk prostate cancer may be managed by either immediate surgery in 
the absence of COVID-19 risk features, or alternatively offered ADT until safe to proceed to surgery, 
although this will have a considerable impact on the patients’ Quality of Life.  Previous observational 
studies have shown that it may be safe to defer surgery in high risk disease by up to 90 days, with the 
use of ADT(25). However, recent modeling estimates have predicted that the COVID-19 pandemic 
may continue for more than 3 months and possibly until a vaccine is developed (26), which is likely to 
delay treatment for a subset of older patients with high-risk prostate cancer and multiple co-
morbidities. Based upon data from the control arm of the STAMPEDE trial, it is anticipated that 32% 
of patients with N0 and 47% of patients with N1 disease within this ADT treated cohort are likely to 
progress over a 2-year period(27). In addition, long-term ADT should be avoided in patients with 
multiple pre-existing co-morbidities due to risk of developing additional co-morbidities(28).  
External beam radiotherapy (EBRT) can also be considered for men with prostate cancer(5). During 
the pandemic this option would possibly have limited use as it requires multiple and frequent hospital 
visits (total 20 to 25 hospital visits within four to five weeks) increasing the risk of COVID-19 for the 
patient(5). The rapid response group of the EAU guidelines suggested to postpone RP until the end of 
the pandemic whilst suggesting that EBRT can still be offered(29). They also suggested keeping 
outpatient visits as low as possible, which contradicts with offering RT during the pandemic. With the 
introduction of “COVID-19 cold” sites the heterogeneous epidemiology of the pandemic is taken into 
account and the multiple risks accompanying can be mitigated and provide surgery as an option for 
patients if necessary. 
Our approach to employ a consensus process was particularly helpful in accomplishing our objectives. 
The Delphi process is useful for complex issues that cannot be subject to clinical studies. For such 
circumstances they are impactful and help in standardizing management. The COVID-19 outbreak has 
created circumstances with great uncertainty that reflected on to urological practice (30). For instance, 
an online survey identified that in 13% of urology practices urologists were encouraged by their 
managers not to ware face masks (30). The time sensitive issues meant that we had to apply an 
accelerated process to achieve our objectives. In our study we adhered to the fundamental principles 
of a Delphi consensus process(7.)The methodology does not dictate the duration of the process but 
due to the nature of urgency and scale of the events we applied an accelerated process. To our 
knowledge this is a novel approach that has not been published before. This was time intensive and to 
achieve success all participants were consented prior to entering the study to adhere to the strict time 
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infectious diseases (PH, JR), nosocomial infections in urology (ZT, TEBJ, FW) and prostate cancer 
surgical management (GS, JC, JK). The accelerated consensus we carried out by adhering to the 
principles of Delphi methodology is novel and we refer to it as a consensus statement. Despite the 
strengths of the work there are some caveats. Firstly, the panel members were from 16 different 
countries around the world, but most were from Europe and the U.S. We therefore concentrated on 
establishing the basic principles for reconfiguring pathways and the IPC measures that can be adjusted 
for local needs. Second, certain items such as double swap test prior to surgery that could be 
beneficial from an IPC point of view did not reach consensus. This was due to concerns of local 
resources of the participants and we have proposed several different alternative pathways as illustrated 
in figure 3. Thirdly, we did not present with a local audit tool for the proposed reconfigured pathways 
yet measuring the impact can be useful. However, this was found to be challenging due to the 
complexity of the pathway. Finally, we only reviewed the pathway for patients with localized prostate 
cancer that opt for radical surgical treatment. Despite this cohort can benefit from the current work 
there is more to be done for reconfiguring the pathways for localized prostate cancer.  
 
Future research related to this work should encompass the measurement of the impact of pathway 
reconfiguration. Such research should prioritize patient related outcomes including cancer 
progression, side effects related to ADT and functional outcomes following delayed surgery. 
Furthermore, studies of “COVID-19-cold” sites should measure the frequency, characteristics and 
implications of COVID-19 cases following surgery. The impact on healthcare workforce should also 
be measured, including their well-being and frequency of hospitals acquired COVID-19. Health-
economic assessment of the “COVID-19-cold” sites could be challenging. Nevertheless, the cost and 
utility of a “COVID-19-cold” site can be estimated against the absence of such a site during the 
pandemic. 
 
In summary, the panel reached consensus on two main domains. Firstly, if COVID-19 remains in 
community surgical procedures for the treatment of prostate cancer should be carried out in a setting 
where the likelihood of COVID-19 related hazards and consequences are kept low. To achieve this, 
the panel agreed on the concepts to which the healthcare environment, patients and healthcare 
workforce must adhere. Secondly, agreement was reached on re-configuring the management 
pathways for prostate cancer patients if significant delay (>3-6 months) in curative management was 
unavoidable. The EAU risk classification system was adopted, and follow-up pathway of each risk 
group was refined. Finally, some of the broader concepts could be adapted to other indications beyond 
prostate cancer surgery.  
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Legends 
 
Table 1. Consensus view on re-organization of management pathways for prostate cancer patients 
eligible for surgical treatment during the COVID-19 pandemic.  
Figure 1. Flow chart of the published literature review to develop the consensus questionnaire. In 
addition, recommendations from WHO, CDC, ECDC and NICE were also reviewed in developing the 
questionnaire.  
Figure 2. Summary of the Consensus process. 
Figure 3. Protocols for prevention of COVID-19 before, during and after surgery. (1) No intervention: 
The patient flow followed prior to the COVID-19 outbreak. This flow does not reduce the risk of 
operating on COVID-19 (+) patients. It exposes the patient, health care professionals and other 
patients on wards to increased risk of COVID-19. The panel advised against operating on patients 
with high likelihood of COVID-19. This scenario would be the most personal protective equipment -
exhaustive approach. (2) Isolation only: In this protocol the patient is kept under isolation for a set 
period of time that would ideally cover the incubation period of COVID-19. If patient remains 
asymptomatic throughout isolation, they can be assumed to be at low risk for COVID-19. 
Implementation of this strategy should account for logistics such as self-isolation vs. isolation at a 
designated site selected by the COVID-cold hospitals. The success of this strategy relies on strict 
isolation and ideally should cover 14 days (97.5% of patients incubation period) (3) Isolation and 
screening protocol. In this protocol the patient is screened for viral RNA at the beginning and the end 
of the isolation period. It could be helpful in different ways. First, it can reduce the duration of the 
isolation period (i.e. Double swap negative within 48 hours low likelihood of COVID-19 carrier). 
Second, if a long isolation is suggested (i.e. 2 weeks) the first screen can be considered as a safety 
check at entrance of self-isolation. Thus, if a patient is positive on first screen that means their surgery 
should be postponed. Therefore, useful in scheduling for theatres. The two-week isolation with double 
swabs at entrance and exit of isolation is the safest option until the self-isolation compliance can be 
secured that negates the exit swab. See supplement VI for different strategies on implementing this 
approach.  (4) Screening only. This protocol assumes utilisation of a rapid diagnostic test that informs 
the clinicians regarding COVID-19 contagiousness and immunity status of individuals. Protocols 2-4 
assume that the COVID-19 outbreak is ongoing and therefore suggests that patient self-isolates after 
discharge until removal of indwelling urinary catheter (consensus by panel). 
Figure 4. A conceptual illustration of surgical prioritization process of prostate cancer patients during 
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COVID-19 pandemic impact on prostate cancer patients 
1. Disruption in health care services for prostate cancer patients 
2. Immediate delay in curative management 
3. Increase in backlog resulting in subsequent delays 
4. Overall increase in likelihood of disease progression 
Basic requirements for a unit to deliver prostate cancer surgery whilst sustaining low risk for 
COVID-19 transmission and consequences  
1. Capacity to screen for COVID-19 
2. Infection prevention and control protocols (IPC) adapted for COVID-19 to be applied for patients 
3. IPCs adapted for COVID-19 to be applied by the health care workforce 
4. Rearrangements of the hospital space and workflow that aims to create and maintain areas with low 
likelihood of COVID-19 transmission hazard  
5. Protocols for rapid isolation of COVID-19-suspected cases detected in the unit into areas separate from 
COVID-19 free wards  
6. Areas with COVID-19-suspected or proven patients that are separate from the prostate cancer screening, 
treatment and follow-up areas 
7. Utilization of telemedicine whenever possible to ensure good communication and planning whilst 
minimising hospital admissions 
The seven items above collectively contribute to decreasing the risk of COVID-19 transmission (likelihood of 
hazard) and its consequences (severity of hazard) within a site that delivers prostate cancer surgery. We 
define such a site as a “COVID-cold site”. 
Resource allocation for COVID-19-free prostate cancer surgical units 
1. In accordance with local resource allocation required for COVID-19 patients 
2. Guided by COVID-19 local epidemiology, overall hospital capacity and its estimated future capacity 
COVID-19 considerations for patients planned for surgery 
Soon before surgery Surgery After surgery 
1. Patient should be screened for 
contagiousness of COVID-19  
2. Application of optimal general 
hygienic measures (i.e. hand 
disinfection) 
3. Account for the lag period 
between becoming contagious 
and testing positive for COVID-
19 and the potential for false 
negative tests*. 
4. If possible, consider self-isolation 
of asymptomatic patient prior to 
surgery, ideally at a location 
1. Patient should be non-
contagious of COVID-19 
2. Consent the patient for 
COVID-19 related risks and 
hazards 
 
1. Self-isolate at home after 
discharge at least until 
indwelling urinary catheter is 
removed safely (including 
travel to and from hospital) 
2. Do not routinely screen for 
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designated by the hospital 




5. Avoid public transportation 
COVID-19 considerations for the healthcare workforce that will deliver prostate cancer 
surgery treatment in COVID-cold sites 
1. Symptomatic healthcare workers should self-isolate and should not attend COVID-19 cold sites 
2. Asymptomatic healthcare workers should be screened and reviewed for COVID-19 prior to a shiftΔ 
3. Evidence for the optimal screening method is unclear (symptoms vs. viral load vs serology vs imaging)* 
4. Liaise with local IPC teams to identify the optimal screening protocol applicable to your region. 
5. Follow future evidence for antibody screening as a tool to establish risk for healthcare worker (an ideal 
workforce may be one that has acquired immunity to COVID-19).  
Personal protective equipment 
(PPE) 
Workflow Theatre space 
1. Assume that all patients and 
healthcare workers may be 
contagious until definitive 
screening tests are available 
2. Use PPE during clinical tasks 
involving face-to-face contact 
with patients 
3. Level and composition of PPE to 
be agreed by local IPC teams for 
each task (i.e. ward rounds, 
change of catheter, surgery) 
4. Evidence is evolving and an 
adaptive approach should be 
implemented 
5. Consider rational use of PPE due 
to perceived shortages in 
supply(8) 
1. Change the working schedule 
to ensure safe delivery of 
service to patients 
2. Adapt the working schedule to 
minimize risk of staff 
contracting COVID-19 outside 
the workspace 
3. Consider developing weekly 
shifts where staff is isolated 
and accommodated on site for 
the full duration of their shift 
(the longer the shifts the better 
for working/screening time 
ratio) 
4. Consider commuting to work 
in private vehicle where 
possible or accommodate 
locally 
1. Decrease number of people in 
theatre 
2. Do not allow observers 
3. Keep training activity to a 
minimum 
4. If robotic surgery is utilized 
and local regulations permit, 
consider placing the console 
outside the theatre to decrease 
PPE consumption and traffic in 
theatre 
5. Consider additional measures 
to minimise risk according to 
type of surgery and exposure to 
types of bodily fluids, aerosols, 
droplets and surgical plume 
6. Consider separate anaesthetic 
room for intubating and 
extubating patients, to decrease 
likelihood of infective aerosol 
(respiratory) dispersal 
7. Consider a safety protocol in 
adherence with local IPC 
guidance for handling of PPE 
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Criteria to use for rationing & prioritization of management of non-metastatic prostate 
cancer patients 
Prostate cancer risk stratification  Patient risk factors for worse outcomes of 
COVID-19  
1. Use the European Association of Urology (EAU) 
risk stratification tool 
2. For intermediate-risk, if needed apply the NCCN 
criteria for further rationing of patients with 
unfavourable risk features 
3. For high-risk if needed apply the NCCN criteria for 
further rationing of patients with very high-risk 
features 
4. The same criteria are applicable for rationing 
management of patients planned for salvage surgical 
treatment 
1. If a patient is prioritized to receive surgery based 
on cancer features, further prioritize with 
COVID risk factors (medical conditions related 
with COVID-19 adverse outcomes, supplement-
I) 
2. If patient is prioritized based on cancer features, 
further prioritize younger men to receive surgery 
3. Prioritize, predicted straight forward cases (i.e. 
no previous abdominal surgery, obesity, TURP) 
Prostate cancer risk groups & relevant management in case of significant delay (>3-6 months) 
of curative treatment 
Low-risk Active surveillance and do not offer surgery during the pandemic even if 
patient is keen for surgery 
Intermediate-risk 1. Do not offer androgen receptor blockers for patients whose treatment has 
been deferred unless there is doubt surrounding diagnostic accuracy/ 
upgrading or upstaging 
2. Arrange first follow-up appointment in three months 
3. Use PSA for follow-up 
4. DRE and TRUS not advised for follow-up during pandemic 
5. MRI may be used (if capacity allows) in select cases where PSA kinetics and 
cancer characteristics cause concern 
High-risk 1. If possible, offer surgery on the basis of risk of disease progression 
2. Consider duration of anticipated delay in surgical treatment prior to 
commencing LHRH analogues  
3. If ADT planned offer LHRH analogues and if not preferred, consider 
Bicalutamide 150mg  
4. Arrange first follow-up appointment in three months 
5. Use PSA and MRI for follow-up: PSA after 3 months and unless concerning 
PSA kinetics MRI after 6 months (if capacity allows)  
6. DRE, TRUS and bone scan are not advised for routine follow-up 
Consideration of pelvic lymph node dissection for patients offered surgery 
1. The balance of survival benefit and harms of ePLND for intermediate and high risk are unclear 
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3. For high risk patients adhere to the decision-making process to which you normally adhered prior to the 
COVID-19 pandemic whilst taking care to avoid inherent risk of complications 
Post-surgical follow up protocols 
1. Aim at keeping hospital visits to a safe minimum 
2. Arrange first postoperative PSA check at 3 months 
3. Where possible (i.e. no peri-operative complications and uneventful catheter removal), use tele-medicine 
for clinical consultations 
* At the time of the consensus and writing the manuscript no screening approach based on either 
single or combination of tests, has been found to offer <5% false negative rate. Testing location (out 
of hospital vs in hospital) process is also unclear.  
Δ Re-arrangement of the working hours of the healthcare workforce is intended to reduce the 
likelihood of getting infected with COVID-19 outside the COVID-19 free hospitals.  
Ψ Isolation strategy is unclear. Possible options are to isolate for 2 weeks prior to surgery at home and 
ensure isolated travel to hospital. Lack of evidence at multiple levels prevented the panel from giving 
specific advice but the concept for isolation was agreed.  
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